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Abstract 
Tranexamic acid is emerging as a useful option for a 
number of clinical indications by virtue of its anti-
fibrinolytic properties that allow better haemostasis and 
lesser blood loss. Herein, the authors have attempted to 
summarize the existing evidence on the possible role of 
tranexamic acid in brain tumour surgeries. 
Keywords: Tranexamic acid, brain tumor, coagulation, 
hemostasis. 
Introduction 
Resection of brain tumours can be encountered with 
significant haemorrhage that may affect complete 
resection and puts the patient at risk. This is especially 
true for certain highly vascular tumours such as a 
significant proportion of meningiomas, 
haemangiopericytomas and haemangioblastomas. 
With the advent of stereotactic technology, the risk of 
intraparenchymal haemorrhage following needle 
biopsy is also of concern especially in deep seated areas 
like the brainstem.1,2 Anaemia and poor haemostasis 
are both in themselves associated with poor outcomes 
in neurosurgery. The general practice in surgical neuro-
oncology is to optimize a patient’s haemostatic profile 
prior to surgery and have blood available for 
transfusion if the need arises. In Pakistan, this raises a 
financial problem of cross matching blood that will 
never be used, a financial burden for the majority of the 
population. Transfusion of blood also comes with its 
attendant risks.3,4 Current practice does not include 
prophylactic use of a pharmaceutical means to reduce 
blood loss. In this review, we examine the data on the 
use of tranexamic acid (TXA) in patients undergoing 
brain tumour resection in terms of volume of blood loss 
and any effect on outcomes. 
Review of Evidence 
Tranexamic acid (TXA) is an anti-fibrinolytic that enjoys 
wide acceptance as a safe and effective means of 
preventing excessive blood loss in both elective and 
emergency surgery. Its use has demonstrable effects in 
reducing blood loss and improvement of outcomes. 
CRASH II, a randomized controlled trial and economic 
evaluation of the effects of TXA on death, vascular 
occlusive events and transfusion requirement in 
bleeding trauma patients, showed that early 
administration of TXA reduced the risk of death in 
bleeding trauma patients. However, there was always a 
question of the risk of intravascular thrombotic 
complications and seizures due to GABA antagonism 
from the administration of TXA in patients with head 
injury or those undergoing neurosurgical interventions, 
which can be devastating.5 CRASH III, that looked at the 
effects of TXA on death, disability, vascular occlusive 
events and other morbidities in patients with acute 
traumatic brain injury, showed that this risk was no 
different from placebo and remained incredibly low.6 
Vlu et al., published a case control study on the back of 
the CRASH II data, which examined the effect of TXA on 
haemostasis in patients undergoing brain tumour 
removal by measuring APPT, PT index, TT, fibrinogen, 
ATIII activity, factor XII-derived fibrinolysis, 
spontaneous euglobulin lysis at four points in time after 
the induction of anaesthesia, before Tranexam 
injection, 30 minutes after Tranexam injection, on the 
next day after the surgery. Blood from jugular and 
peripheral veins was analyzed simultaneously. 
According to their data, which was not publicly 
available at the time of writing this review, TXA caused 
a significant decrease in fibrinolytic activity and 
decreased duration of time required to achieve 
haemostasis and visual inspection of bleeding from the 
wound. We believe their study design can be improved, 
although they did report a decrease in wound drain 
output.7 Beynon et al., have published an interesting 
case report of a patient with coagulopathy with 
uncertain pathology who needed a stereotactic 
brainstem biopsy. The authors were able to perform it 
safely by administering TXA and desmopressin without 
a verifiable diagnosis for her coagulopathy.2 A 2011 
report by Bharat et al., states that TXA does not have 
widespread use in neurosurgery, but they found it 
useful in an anecdotal report in which TXA 
administration arrested severe continuous 
haemorrhage in a child with choroid plexus papilloma. 
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This was preceded by maximum standard efforts to 
secure haemostasis.8 Phi et al., have described two 
cases of infants who underwent surgery to remove a 
similar tumour (choroid plexus papilloma) and in their 
experience, TXA administration was associated with 
blood loss that was less than 20% of the child’s total 
circulating blood volume. When compared to another 
similar case in which TXA was not used blood loss was 
more than 100% of the total circulating blood volume.9 
The most useful evidence for the use of TXA in brain 
tumour surgery comes from its use in meningioma and 
complex skull base surgery. Mebel et al., performed a 
retrospective cohort study to compare the rate of 
perioperative transfusion between patients who did 
and did not receive TXA during resection of complex 
skull base tumours. The majority of these tumours were 
acoustic neuromas and meningiomas. They concluded 
that routine use of TXA reduces the risk of perioperative 
transfusion in this group of patients and is an 
independent determinant (adjusted OR 0.15–0.65            
[p value = 0.002]).10 Hooda et al., published the first RCT 
for the use of TXA in intracranial meningioma surgery. 
They concluded that there was a 27% reduction in 
estimated blood loss with the use of TXA (p <0.05). 
However, the risk of requiring a blood transfusion was 
not significantly lower in the TXA group despite a lower 
trend (p = 0.07). The number of patients who received a 
transfusion was similar in both groups.11 Nilsson et al., 
studied the coagulation changes that occur 
perioperatively in 40 patients undergoing neurosurgery 
with hydroxyethylstarch (HES) as fluid therapy. Their 
findings of mostly unaltered coagulation profile do not 
support the routine use of TXA in patients undergoing 
elective neurosurgery.12 
Conclusion 
We believe there is good evidence to suggest that TXA 
may be used prophylactically in intracranial 
meningioma surgery to reduce absolute blood loss but 
the risk of transfusion may not be significantly reduced. 
In paediatric highly vascular tumours such as choroid 
plexus papilloma,its use may be warranted considering 
the favourable side effect profile although the notion is 
based entirely on anecdotal reports. 
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